pSivida Corp



The pSivida product portfolio is composed of approved and development stage products and technologies with a primary focus on miniaturized, sustained-release drug delivery systems. Our lead development product, ILUVIEN® (fuocinolone acetonide for the treatment of diabetic macular edema) is under FDA review following the completion of two, Phase III, clinical trials. The NDA was submitted in May 2011. In addition, we are evaluating multiple therapeutic areas where we believe our technology has potential application. In these areas, we are pursuing partnerships to further the development pipeline

Click here for more information on partnering with pSivida. »

Pipeline Chart